BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 23, 2012--
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that Chris
Boerner, Ph.D. has been promoted to Senior Vice President, Commercial.
Dr. Boerner joined Seattle Genetics in November 2010 as Vice President,
Marketing, and has served as a key member of the commercial organization
involved in the launch of ADCETRIS™ (brentuximab vedotin). He replaces
Bruce Seeley, former Executive Vice President, Commercial, who is
leaving Seattle Genetics to pursue other opportunities.
“Chris has been a strategic leader in our commercial organization for
more than a year, and has contributed significantly to the successful
launch of ADCETRIS,” said Clay B. Siegall, Ph.D., President and Chief
Executive Officer of Seattle Genetics. “He has brought to Seattle
Genetics extensive experience from the commercialization and life-cycle
management of several oncology products. We anticipate a seamless
transition as we continue to execute on our commercial priorities to
bring ADCETRIS to relapsed Hodgkin lymphoma and systemic ALCL patients
in need.”
“Bruce has built a strong sales, marketing and reimbursement team that
is executing extremely well on the commercialization of ADCETRIS,” added
Dr. Siegall. “We thank him for his contributions in preparing the
company for its transition to a commercial organization and his
leadership through the early launch phase. We wish him the best in his
future endeavors.”
Prior to Seattle Genetics, Chris Boerner spent more than eight years at
Genentech, a member of the Roche Group, where he served in a variety of
commercial roles, including Director of Marketing on Avastin and
Director of Avastin franchise management. Additionally, he served in a
variety of commercial roles across multiple disease areas, including
solid tumor oncology, lymphoma and immunology. Dr. Boerner joined
Genentech from McKinsey & Company, a global strategic management
consulting firm, where he worked on a variety of pharmaceutical sales
and marketing engagements. Prior to joining Seattle Genetics in 2010, he
most recently led the marketing team at Dendreon. Dr. Boerner received
his Ph.D. and M.A. in Business Administration from the Haas School of
Business at the University of California, Berkeley, and holds an A.B. in
Economics and History from Washington University in St. Louis.
About Seattle Genetics
Seattle Genetics is a biotechnology company focused on the development
and commercialization of monoclonal antibody-based therapies for the
treatment of cancer. The U.S. Food and Drug Administration granted
accelerated approval of ADCETRIS in August 2011 for two indications.
ADCETRIS is being developed in collaboration with Millennium: The Takeda
Oncology Company. In addition, Seattle Genetics has three other
clinical-stage ADC programs: SGN-75, ASG-5ME and ASG-22ME. Seattle
Genetics has collaborations for its ADC technology with a number of
leading biotechnology and pharmaceutical companies, including Abbott,
Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline,
Millennium, Pfizer and Progenics, as well as ADC co-development
agreements with Agensys, an affiliate of Astellas, and Genmab. More
information can be found at www.seattlegenetics.com.
Certain of the statements made in this press release are forward
looking, such as those, among others, relating to the company’s
expectations for continued commercial success of ADCETRIS. Actual
results or developments may differ materially from those projected or
implied in these forward-looking statements. Factors that may cause such
a difference include, among others, that adverse events for ADCETRIS
adversely affect the ability to successfully market ADCETRIS or that
planned and future clinical trials do not support additional approvals
in earlier lines of therapy or other malignancies. More information
about the risks and uncertainties faced by Seattle Genetics is contained
in the company’s Form 10-Q for the quarter ended September 30, 2011
filed with the Securities and Exchange Commission. Seattle Genetics
disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Source: Seattle Genetics, Inc.
Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
ppinkston@seagen.com
